2
The Albert J. Finestone, M.D. Office for Continuing Medical Education Temple University School of Medicine 3440 N. Broad Street, Kresge 100 Philadelphia, PA 19140 VISIT OUR WEBSITE www.temple.edu/cme Share this brochure with your colleagues and other healthcare professionals NON-PROFIT ORG. U.S. POSTAGE PAID PERMIT NO. 226 PHILADELPHIA, PA 2013 WEDNESDAY, OCTOBER 23, 2013 6:30-8:30 PM LOCATION: The Palm Restaurant 2801 Pacific Avenue • Atlantic City, NJ 08401 GUEST SPEAKER: Kevin Brown, MD, National Jewish Health, Denver, CO PRESENTED BY: Temple University School of Medicine Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. TARGET AUDIENCE: Pulmonologists, Primary Care Physicians, Respiratory Therapists, Physician Assistants, Nurse Practitioners, and Nurses involved in the treatment of IPF LEARNING OBJECTIVES: After the completion of this activity, participants should be able to: • Explain the role of evidence-based guidelines in the diagnosis of IPF • Describe pharmacologic and non-pharmacologic approaches to treating IPF • Discuss the importance of patient lifestyle management tools • Discuss various health related quality of life (QOL) measures used in IPF clinical trials with respect to patient outcomes ACCREDITATION STATEMENT: Temple University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. CERTIFICATION STATEMENT: Temple University School of Medicine designates this live activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. DISCLOSURE POLICY: It is the policy of the Temple University School of Medicine, The Albert J. Finestone, M.D., Office for Continuing Medical Education that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/ unapproved uses of drugs or devices during their presentation(s). Temple University School of Medicine, Office for Continuing Medical Education has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made prior to the activity. 2 AMA PRA Category 1 Credits™

What is New in Idiopathic Pulmonary Fibrosis?

Embed Size (px)

Citation preview

Page 1: What is New in Idiopathic Pulmonary Fibrosis?

The

Albe

rt J.

Fin

esto

ne, M

.D.

Offi

ce fo

r Con

tinui

ng M

edic

al E

duca

tion

Tem

ple

Uni

vers

ity S

choo

l of M

edic

ine

3440

N. B

road

Str

eet,

Kres

ge 1

00Ph

ilade

lphi

a, P

A 19

140

VIS

IT O

UR

WE

BSI

TE

ww

w.t

empl

e.ed

u/cm

e

Shar

e th

is b

roch

ure

wit

h

you

r co

lleag

ues

an

d o

ther

h

ealt

hca

re p

rofe

ssio

nal

s

NO

N-P

ROFI

T O

RG.

U.S.

PO

STAG

E

PAID

PERM

IT N

O. 2

26PH

ILAD

ELPH

IA, P

A

What Is NeW IN IdIoPathIc PulMoNary FIbrosIs?

2013

WedNesday, october 23, 20136:30-8:30 PM

locatIoN: thepalmrestaurant2801pacificavenue•atlanticcity,NJ08401

Guest sPeaKer: KevinBrown,mD,NationalJewishhealth,Denver,co

PreseNted by: templeUniversitySchoolofmedicine

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

taRget audience:Pulmonologists, Primary Care Physicians, Respiratory Therapists, Physician Assistants, Nurse Practitioners, and Nurses involved in the treatment of IPF

leaRning obJectives:After the completion of this activity, participants should be able to:

• Explain the role of evidence-based guidelines in the diagnosis of IPF

• Describe pharmacologic and non-pharmacologic approaches to treating IPF

• Discuss the importance of patient lifestyle management tools

• Discuss various health related quality of life (QOL) measures used in IPF clinical trials with respect to patient outcomes

accReditation statement:Temple University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

ceRtiFication statement:Temple University School of Medicine designates this live activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

disclosuRe policy:It is the policy of the Temple University School of Medicine, The Albert J. Finestone, M.D., Offi ce for Continuing Medical Education that the speaker and provider disclose real or apparent confl icts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Temple University School of Medicine, Offi ce for Continuing Medical Education has established policies in place that will identify and resolve all confl icts of interest prior to this educational activity. Detailed disclosure will be made prior to the activity. WedNesday, october 23, 2013

2801pacificavenue•atlanticcity,NJ08401

2 AMA PRA Category 1 Credits™

Page 2: What is New in Idiopathic Pulmonary Fibrosis?

RegistRation FoRm

What is neW in idiopathic pulmonaRy FibRosis?

RegistRation is FRee. seating is limited – RegistRation is RequiRed complimentaRy valet paRking

RetuRn to:Chris Rausch Office for Continuing Medical Education Temple University School of Medicine 3440 N. Broad Street, Kresge 100 Philadelphia, PA 19140 215-707-4787 or 800-23-TUCME or FAX 215-707-8268 Register online at www.temple.edu/cme

How did you hear about this program?

Name:

Degree:

Specialty:

aDDreSS:

city: State: Zip:

DaytimephoNe:

email:

If you have special needs that we can address to make your participation more meaningful and enjoyable, please contact our office at (215) 707-4787.

Faculty:

Kevin K. Brown, MDProfessor and Vice ChairmanDepartment of MedicineNational Jewish HealthDenver, CO

Gerard Criner, MDChair, Department of Medicine Professor of MedicineDirector, Division of Pulmonary and Critical Care MedicineTemple University School of Medicine

Irene Swift, MDAssistant Professor of MedicinePulmonary and Critical Care MedicineTemple University School of Medicine

Yoshiya Toyoda, MDProfessor of SurgeryCardiothoracic SurgeryTemple University School of Medicine

Michelle Vega-Olivo, MSN, CRNP, FNP-BCPulmonary Nurse PractitionerTemple Lung Center

pRogRam agenda:

6:15 – 6:25 PM Registration and Dinner

6:25 – 6:30 PM Introductory RemarksGerard Criner, MD

6:30 – 6:55 PM Diagnosing IPF Based on Evidence-Based Guidelines Irene Swift, MD

6:55 – 7:25 PM Pharmacologic and Non-Pharmacologic Approach to Treating IPF Kevin K. Brown, MD

7:25 – 7:45 PM Patient Lifestyle Management ToolsMichelle Vega-Olivo, MSN, CRNP, FNP-BC

7:45 – 8:15 PM Management of Advanced-Stage DiseaseYoshiya Toyoda, MD

8:15 – 8:30 PM Roundtable Discussion and Q&AGerard Criner, MD

8:30 PM Adjourn

What Is NeW IN IdIoPathIc PulMoNary FIbrosIs?

2013